NASDAQ:GNMXAevi Genomic Medicine Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aevi Genomic Medicine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.17 0.00 (0.00 %) (As of 02/3/2020) Add Compare Share Today's Range$0.15Now: $0.17▼$0.1850-Day Range$0.17MA: $0.17▼$0.1952-Week Range$0.11Now: $0.17▼$0.35Volume2.95 million shsAverage Volume3.16 million shsMarket Capitalization$12.89 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aevi Genomic Medicine. Previous Next 2.3 Community Rank Outperform VotesAevi Genomic Medicine has received 197 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAevi Genomic Medicine has received 238 “underperform” votes. (Add your “underperform” vote.)Community SentimentAevi Genomic Medicine has received 54.71% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote “Outperform” if you believe GNMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAevi Genomic Medicine does not currently pay a dividend.Dividend GrowthAevi Genomic Medicine does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aevi Genomic Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders43.80% of the stock of Aevi Genomic Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.03% of the stock of Aevi Genomic Medicine is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aevi Genomic Medicine is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aevi Genomic Medicine is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAevi Genomic Medicine has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNMX Previous SymbolNASDAQ:MDGN CUSIPN/A CIK1138776 Webwww.aevigenomics.com Phone610-254-4201Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-30,770,000.00 Net MarginsN/A Return on Equity-898.31% Return on Assets-286.73%Miscellaneous Employees14 Outstanding Shares77,714,000Market Cap$12.89 million Next Earnings DateN/A OptionableOptionable Receive GNMX News and Ratings via Email Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter. Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions How were Aevi Genomic Medicine's earnings last quarter? Aevi Genomic Medicine Inc (NASDAQ:GNMX) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's earnings history. Has Aevi Genomic Medicine been receiving favorable news coverage? News headlines about GNMX stock have trended very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aevi Genomic Medicine earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAevi Genomic Medicine. Who are some of Aevi Genomic Medicine's key competitors? Some companies that are related to Aevi Genomic Medicine include Polarityte (PTE), Creative Realities (CRDF), TrovaGene (TROV), Acorda Therapeutics (ACOR), aTyr Pharma (LIFE), Curis (CRIS), Pharmacyte Biotech (PMCB), BioCardia (BCDA), Titan Pharmaceuticals (TTNP), Entera Bio (ENTX), Genetic Technologies (GENE), Vitro Diagnostics (VODG), TRACON Pharmaceuticals (TCON), Seneca Biopharma (SNCA) and Enzon Pharmaceuticals (ENZN). View all competitors. What other stocks do shareholders of Aevi Genomic Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include SCYNEXIS (SCYX), Novavax (NVAX), Ibio (IBIO), Immunomedics (IMMU), Protalix Biotherapeutics (PLX), Actinium Pharmaceuticals (ATNM), Biocept (BIOC), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO) and Rigel Pharmaceuticals (RIGL). Who are Aevi Genomic Medicine's key executives? Aevi Genomic Medicine's management team includes the following people: Mr. Michael F. Cola, CEO, Pres & Director (Age 59)Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)Dr. Garry A. Neil, Chief Scientific Officer (Age 65) What is Aevi Genomic Medicine's stock symbol? Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX." What is Aevi Genomic Medicine's stock price today? One share of GNMX stock can currently be purchased for approximately $0.17. How big of a company is Aevi Genomic Medicine? Aevi Genomic Medicine has a market capitalization of $12.89 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Aevi Genomic Medicine employs 14 workers across the globe. What is Aevi Genomic Medicine's official website? The official website for Aevi Genomic Medicine is www.aevigenomics.com. How can I contact Aevi Genomic Medicine? Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
